Press "Enter" to skip to content

The Finance Herald

Silexion Therapeutics Achieves Preclinical Metastasis Milestone Data as Company Advances Toward Pivotal Clinical Trials

Latest preclinical results validate systemic delivery approach, positioning SIL204 for Phase 2/3 initiation in first half of 2026 Silexion Therapeutics (NASDAQ: SLXN) today announced groundbreaking preclinical data demonstrating that its…